Antiverse
PrivateLast Round
Series A
Mar 3, 2026
Total Funding Raised
$18.93M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antiverse is a biotechnology company that develops an AI-driven platform for the design and discovery of antibody therapeutics against challenging drug targets such as G-protein coupled receptors and ion channels.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antiverse Comparables
Compare Antiverse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| immunitoAI | 91% | |
| Aureka Biotechnologies | 88% | |
| MOLCURE Inc. | 87% |
Antiverse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 3, 2026 | ||||
| Seed | Oct 15, 2024 | ||||
| Seed | Mar 1, 2023 | ||||
| Seed | Mar 15, 2021 | ||||
| Grant | Jul 1, 2018 |
Key People
Founding team and executive leadership
Antiverse Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ACF Investors | Seed |
| Future Planet Capital Regional | Seed |
| Deep Science Ventures | Seed |
| Cambridge Angels | Seed |
| Soulmates Ventures | Series A |
| Accelerate@Babraham | Grant |
| AngelHub | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 324% MoM, reaching 5.1K.
- Apr 1, 2026
Added Tensor, an investment firm, as a customer.
Antiverse Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Antiverse's valuation, stock price, and market status.
Is Antiverse a public or private company?
Antiverse is a private company.
What is the current stock price of Antiverse?
Antiverse is a private company, so its shares have no public market price. Caplight tracks Antiverse's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antiverse worth (valuation)?
Valuation information for Antiverse is not publicly available.
Can I buy Antiverse stock?
Antiverse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antiverse's last funding round?
Antiverse's most recent funding round was Series A on March 3, 2026.
Who are the main investors in Antiverse?
Key investors in Antiverse include Soulmates Ventures, Kadmos Capital, i&i Prague.
Will Antiverse IPO soon?
No public IPO plans have been announced for Antiverse.
How can I track Antiverse secondary market activity?
Caplight tracks bids, offers, and trades in Antiverse's shares on secondary markets.